1. Home
  2. PHAT vs NBN Comparison

PHAT vs NBN Comparison

Compare PHAT & NBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHAT
  • NBN
  • Stock Information
  • Founded
  • PHAT 2018
  • NBN 1872
  • Country
  • PHAT United States
  • NBN United States
  • Employees
  • PHAT N/A
  • NBN N/A
  • Industry
  • PHAT Biotechnology: Pharmaceutical Preparations
  • NBN Major Banks
  • Sector
  • PHAT Health Care
  • NBN Finance
  • Exchange
  • PHAT Nasdaq
  • NBN Nasdaq
  • Market Cap
  • PHAT 769.0M
  • NBN 811.6M
  • IPO Year
  • PHAT 2019
  • NBN N/A
  • Fundamental
  • Price
  • PHAT $11.70
  • NBN $94.82
  • Analyst Decision
  • PHAT Strong Buy
  • NBN Hold
  • Analyst Count
  • PHAT 5
  • NBN 1
  • Target Price
  • PHAT $16.40
  • NBN $115.00
  • AVG Volume (30 Days)
  • PHAT 1.3M
  • NBN 92.2K
  • Earning Date
  • PHAT 11-06-2025
  • NBN 10-28-2025
  • Dividend Yield
  • PHAT N/A
  • NBN 0.04%
  • EPS Growth
  • PHAT N/A
  • NBN 32.98
  • EPS
  • PHAT N/A
  • NBN 10.08
  • Revenue
  • PHAT $114,039,000.00
  • NBN $204,086,000.00
  • Revenue This Year
  • PHAT $213.11
  • NBN $17.75
  • Revenue Next Year
  • PHAT $91.84
  • NBN $9.91
  • P/E Ratio
  • PHAT N/A
  • NBN $9.40
  • Revenue Growth
  • PHAT 1049.82
  • NBN 33.67
  • 52 Week Low
  • PHAT $2.21
  • NBN $75.50
  • 52 Week High
  • PHAT $19.50
  • NBN $113.01
  • Technical
  • Relative Strength Index (RSI)
  • PHAT 50.37
  • NBN 33.58
  • Support Level
  • PHAT $10.33
  • NBN $93.45
  • Resistance Level
  • PHAT $12.97
  • NBN $98.14
  • Average True Range (ATR)
  • PHAT 0.89
  • NBN 2.82
  • MACD
  • PHAT -0.11
  • NBN -1.32
  • Stochastic Oscillator
  • PHAT 45.41
  • NBN 6.75

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

About NBN Northeast Bank

Northeast Bank provides banking and financial services to individual and corporate customers in the United States. The firm conducts its loan-related activities through two primary channels: the Community Banking Division, and the Small Business Administration (SBA) National Division. Its loan portfolio comprises residential mortgage loans; multi-family and other commercial real estate loans; commercial and industrial loans, consumer loans, and small business administration loans. The firm also provides telephone banking, online banking, mobile banking, and remote deposit capture services. The revenue of the company is derived principally from interest and dividends from the bank.

Share on Social Networks: